Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

47.6%

10 terminated/withdrawn out of 21 trials

Success Rate

41.2%

-45.3% vs industry average

Late-Stage Pipeline

38%

8 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results7 terminated

Enrollment Performance

Analytics

N/A
8(47.1%)
Phase 4
8(47.1%)
Phase 1
1(5.9%)
17Total
N/A(8)
Phase 4(8)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT07468617Not ApplicableNot Yet Recruiting

Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Role: lead

NCT03893370Not ApplicableActive Not Recruiting

RejuvenAir® System Trial for COPD With Chronic Bronchitis

Role: lead

NCT03892694Not ApplicableActive Not Recruiting

Metered Cryospray for the Treatment of Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Role: lead

NCT02483637Not ApplicableCompleted

Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients

Role: lead

NCT02464904Not ApplicableTerminated

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

Role: collaborator

NCT00321958Terminated

Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer

Role: collaborator

NCT01787864Completed

Prevalence of Dysplasia of the Gastric Cardia

Role: collaborator

NCT02106143Not ApplicableCompleted

RejuvenAir™ System Lobectomy Safety and Histology Study

Role: lead

NCT02483052Phase 1Completed

RejuvenAir Lobectomy for Safety and Histology

Role: lead

NCT01845454Not ApplicableTerminated

A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

Role: lead

NCT01903850Phase 4Withdrawn

TruFreeze™ Airway Obstruction: TAO STUDY

Role: lead

NCT00747448Completed

CryoSpray Ablation (TM) GI Patient Registry

Role: lead

NCT00754468Phase 4Completed

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

Role: lead

NCT00747461Phase 4Terminated

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

Role: lead

NCT00756197Phase 4Withdrawn

CryoSpray Ablation(TM)to Determine Safety and Feasibility in Radiation Induced Proctitis

Role: lead

NCT00748085Not ApplicableTerminated

CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)

Role: lead

NCT00747916Phase 4Terminated

Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS")

Role: lead

NCT00785239Withdrawn

CryoSpray Ablation(tm)Thoracic Patient Registry

Role: lead

NCT00526786Phase 4Terminated

Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus

Role: lead

NCT00747773Phase 4Completed

Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung

Role: lead